Fulcrum Therapeutics (FULC) Accumulated Depreciation & Amortization (2019 - 2025)
Fulcrum Therapeutics (FULC) has disclosed Accumulated Depreciation & Amortization for 7 consecutive years, with $15.6 million as the latest value for Q4 2025.
- On a quarterly basis, Accumulated Depreciation & Amortization rose 9.75% to $15.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $15.6 million, a 9.75% increase, with the full-year FY2025 number at $15.6 million, up 9.75% from a year prior.
- Accumulated Depreciation & Amortization was $15.6 million for Q4 2025 at Fulcrum Therapeutics, up from $15.3 million in the prior quarter.
- In the past five years, Accumulated Depreciation & Amortization ranged from a high of $15.6 million in Q4 2025 to a low of $6.7 million in Q1 2021.
- A 5-year average of $11.9 million and a median of $12.3 million in 2023 define the central range for Accumulated Depreciation & Amortization.
- Peak YoY movement for Accumulated Depreciation & Amortization: skyrocketed 54.83% in 2021, then increased 9.75% in 2025.
- Fulcrum Therapeutics' Accumulated Depreciation & Amortization stood at $8.3 million in 2021, then increased by 28.94% to $10.7 million in 2022, then rose by 19.68% to $12.8 million in 2023, then grew by 11.73% to $14.3 million in 2024, then rose by 9.75% to $15.6 million in 2025.
- Per Business Quant, the three most recent readings for FULC's Accumulated Depreciation & Amortization are $15.6 million (Q4 2025), $15.3 million (Q3 2025), and $15.0 million (Q2 2025).